jun 6, 2019: 9 a.m. - 10:15 a.m.
106AB, Level 100
There's no denying that investments and drug development in rare and orphan diseases have increased tremendously over the last few years. It appears that venture capital is focusing on investments in this category because there seems to be a more capital efficient path to market along with dire patient need. This discussion will dive into the waves of change that have impacted the investments in this field, how investors balance the patient need with the need to get a return on investment and patient stories that have been instrumental in investments to date.